目的 探討金蕎麥膠囊聯(lián)合吸入用布地奈德混懸液治療小兒支氣管哮喘的臨床療效。方法 選取2021年6月—2022年6月重慶市榮昌區(qū)人民醫(yī)院接受治療的92例支氣管哮喘患兒，按照隨機數(shù)字表法將所有患兒分為對照組和治療組，每組各46例。對照組患兒霧化吸入吸入用布地奈德混懸液，將藥液擠入霧化器的藥杯內(nèi)進行，1 mg/次，2次/d；治療組在對照組基礎(chǔ)上口服金蕎麥膠囊，3粒/次，3次/d。兩組患兒均連續(xù)治療2周。觀察兩組的臨床療效，比較兩組的癥狀緩解時間、肺功能指標(biāo)、炎癥因子和免疫功能指標(biāo)。結(jié)果 治療后，治療組患兒總有效率為95.65%，顯著高于對照組總有效率82.61%（P＜0.05）。治療后，治療組咳嗽消退時間、哮鳴音改善時間、喘息好轉(zhuǎn)時間明顯短于對照組（P＜0.05）。治療后，兩組患者用力肺活量（FVC）、第1秒用力呼氣量（FEV₁）、最大呼吸峰流速值（PEF）高于治療前（P＜0.05）；治療組FVC、FEV₁、PEF明顯高于對照組（P＜0.05）。治療后，兩組患者血清C反應(yīng)蛋白（CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）水平低于治療前（P＜0.05）；與對照組相比，治療組血清CRP、TNF-α、IL-6水平更低（P＜0.05）。治療后，兩組患者血清免疫球蛋白A（IgA）、免疫球蛋白G（IgG）、免疫球蛋白M（IgM）水平高于治療前（P＜0.05）；與對照組相比，治療組血清IgA、IgG、IgM水平更高（P＜0.05）。結(jié)論 金蕎麥膠囊聯(lián)合吸入用布地奈德混懸液治療小兒支氣管哮喘具有較好的臨床療效，可有效緩解患兒的臨床癥狀，改善肺功能，降低炎癥反應(yīng)，提高免疫力，且安全性較高。

Objective To investigate the clinical effect of Jinqiaomai Capsules combined with Budesonide Suspension for inhalation in treatment of bronchial asthma in children. Methods Children (92 cases) with bronchial asthma in Chongqing Rongchang District People's Hospital from June 2021 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 46 cases. Children in the control group were nebulization inhalation administered with Budesonide Suspension for inhalation, the drug solution was squeezed into the nebulizer cup, 1 mg/time, twice daily. Children in the treatment group were po administered with Jinqiaomai Capsules on the basis of the control group, 3 grains/time, three times daily. Children in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the symptom relief time, lung function indicators, and the serum levels of CRP, TNF-α, IL-6, IgA, IgG, and IgM in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.65%, significantly higher than the control group's total effective rate of 82.61% (P < 0.05). After treatment, the cough resolution time, wheezing sound improvement time, and wheezing improvement time in the treatment group were significantly shorter than those in the control group (P < 0.05). After treatment, FVC, FEV₁, and PEF of two groups were higher than before treatment (P < 0.05). FVC, FEV₁, and PEF in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the serum levels of CRP, TNF-α, and IL-6 in two groups were lower than before treatment (P < 0.05). Compared with the control group, the levels of serum CRP, TNF-α, and IL-6 in the treatment group were lower (P < 0.05). After treatment, the serum levels of IgA, IgG, and IgM in two groups were higher than before treatment (P < 0.05). Compared with the control group, the levels serum of IgA, IgG, and IgM in the treatment group were higher (P < 0.05). Conclusion Jinqiaomai Capsules combined with Budesonide Suspension for inhalation has clinical curative effect in treatment of bronchial asthma in children, can effectively relieve clinical symptoms of children, improve lung function, reduce inflammation, improve immunity, with good safety.

R974

白求恩醫(yī)學(xué)科學(xué)研究基金項目